The Estrogen Receptor Joins Other Cancer Biomarkers as a Predictor of Outcome

Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are urgently needed. In this review, we explore the estrogen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Leslie, Kimberly K., Thiel, Kristina W., Reyes, Henry D., Yang, Shujie, Zhang, Yuping, Carlson, Matthew J., Kumar, Nirmala S., Dai, Donghai D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816067/
https://www.ncbi.nlm.nih.gov/pubmed/24223042
http://dx.doi.org/10.1155/2013/479541
Descripción
Sumario:Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are urgently needed. In this review, we explore the estrogen receptor as the most studied biomarker and the best predictor for response for endometrial cancer reported to date.

Ejemplares similares